Cybersecurity Information Exchange with Privacy (CYBEX-P) and TAHOE – A Cyberthreat Language

Cybersecurity information sharing (CIS) is envisioned to protect organizations more effectively from advanced cyberattacks. However, a completely automated CIS platform is not widely adopted. The major challenges are: (1) the absence of advanced data analytics capabilities and (2) the absence of a robust cyberthreat language (CTL). This work introduces Cybersecurity Information Exchange with Privacy (CYBEX-P), as a CIS framework, to tackle these challenges. CYBEX-P allows organizations to share heterogeneous data from various sources. It correlates the data to automatically generate intuitive reports and defensive rules. To achieve such versatility, we have developed TAHOE - a graph-based CTL. TAHOE is a structure for storing, sharing, and analyzing threat data. It also intrinsically correlates the data. We have further developed a universal Threat Data Query Language (TDQL). In this work, we propose the system architecture for CYBEX-P. We then discuss its scalability along with a protocol to correlate attributes of threat data. We further introduce TAHOE & TDQL as better alternatives to existing CTLs and formulate ThreatRank - an algorithm to detect new malicious events.We have developed CYBEX-P as a complete CIS platform for not only data sharing but also for advanced threat data analysis. To that end, we have developed two frameworks that use CYBEX-P infrastructure as a service (IaaS). The first work is a phishing URL detector that uses machine learning to detect new phishing URLs. This real-time system adapts to the ever-changing landscape of phishing URLs and maintains an accuracy of 86%. The second work models attacker behavior in a botnet. It combines heterogeneous threat data and analyses them together to predict the behavior of an attacker in a host infected by a bot malware. We have achieved a prediction accuracy of 85-97% using our methodology. These two frameworks establish the feasibility of CYBEX-P for advanced threat data analysis for future researchers

An Analysis of Air Traffic Controllers’ Job Satisfaction

The air traffic controllers\u27 job is one of the most hectic in today’s world, predominantly due to its safety-critical operations and altering expectations. The primary purpose of this paper is to provide a holistic directory of determinants and synthesized reinforcements for air traffic controllers\u27 job satisfaction. Researchers in the past have put the spotlight on individual air traffic controller’s technical job satisfaction factors, such as impacts from remote tower operation, airplane trajectory changes, and dynamic air traffic situations. However, none described the connection among those factors and how adjusting those factors can enhance the cognitive components related to their job satisfaction. This paper\u27s in-depth analysis identified factors contributing to air traffic controllers\u27 job satisfaction based on past literature. It is intended to increase understanding and improve knowledge for future researchers and practitioners. The five predominant factors identified for air traffic controllers’ job satisfaction are ambiguity of job functions, overwhelming workload, complex task performance and uncertain work demand, job fatigue, and work-family conflict. Some effective methods to increase air traffic controllers’ job satisfaction are regular break between shifts, technological advancement to facilitate jobs, and sound insulations

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570